KIT and neoplasm: Immunohistochemical analysis of the prognostic value of CK5, CD117, and EGFR showed a longer DFS and OS periods for TNBC patients (with the tumor expressing at least one positive biomarker CK5, CD117 and/or EGFR) in contrast to the findings reported in other studies.